Skip to the answer

Trastuzumab Injection Uses, Dosage, Side Effects and Interactions

Brand names
Herceptin

Herceptin is the original trastuzumab, made by Genentech. Its biosimilars are Ogivri, Herzuma, Ontruzant and Trazimera, and 2 more. It comes as an injection.

See Herceptin and its biosimilars

Herzuma

Herzuma (trastuzumab-pkrb) is Celltrion’s biosimilar to Herceptin, approved by the FDA in December 2018. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.

How Herzuma compares with Herceptin

Kanjinti

Kanjinti (trastuzumab-anns) is Amgen’s biosimilar to Herceptin, approved by the FDA in June 2019. The FDA has not rated it interchangeable with Herceptin.

How Kanjinti compares with Herceptin

Ogivri

Ogivri (trastuzumab-dkst) is Biocon Biologics’s biosimilar to Herceptin, approved by the FDA in December 2017. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.

How Ogivri compares with Herceptin

Trazimera

Trazimera (trastuzumab-qyyp) is Pfizer Ireland Pharmaceuticals’s biosimilar to Herceptin, approved by the FDA in March 2019. The FDA has not rated it interchangeable with Herceptin.

How Trazimera compares with Herceptin

Ontruzant

Ontruzant (trastuzumab-dttb) is Samsung Bioepis’s biosimilar to Herceptin, approved by the FDA in January 2019. The FDA has not rated it interchangeable with Herceptin. It comes as an injection.

How Ontruzant compares with Herceptin

Hercessi

Hercessi (trastuzumab-strf) is Accord BioPharma’s biosimilar to Herceptin, approved by the FDA in April 2024. The FDA has not rated it interchangeable with Herceptin.

How Hercessi compares with Herceptin

Herceptin is the original trastuzumab. The FDA has approved 6 biosimilars of it, such as Ogivri and Herzuma, and they share this page. What is a biosimilar? ↓

Trastuzumab Injection is an intravenous (IV) medicine that targets HER2, used to treat HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction cancer.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Trastuzumab InjectionType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Trastuzumab Injection in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Trastuzumab is a targeted antibody for breast cancer and advanced stomach or gastroesophageal junction (where the esophagus joins the stomach) cancer whose tumors make too much HER2, a growth protein; it slows those cells and helps the immune system attack them, and it has anchored HER2-positive treatment since about 1998, with several FDA-licensed biosimilar versions. Many people tolerate it better than the chemotherapy it usually joins; fever and chills with the first infusion, tiredness and diarrhea are most common. Its boxed warning covers heart weakening, serious infusion and lung reactions, and harm to an unborn baby, so report new breathlessness, ankle swelling, a racing heartbeat or sudden weight gain.

Key Takeaways From the HelloPharmacist Team

  • Expect a clinic IV infusion weekly or every three weeks, the first one longer, for about a year in early breast cancer.
  • Plan on a heart scan before starting and about every 3 months during treatment, since heart weakening can happen without symptoms.
  • Report trouble breathing, dizziness or face or throat swelling right away, whether during the infusion or within the next 24 hours.
  • If you could become pregnant, use effective birth control throughout treatment and for 7 months after the last dose.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Trastuzumab Injection.

Trastuzumab products can cause serious heart problems, serious infusion and lung reactions, and harm to an unborn baby.

  • Heart: It can weaken the heart, causing heart failure or a drop in heart pumping function (LVEF), even without symptoms. Risk is highest with anthracycline chemotherapy. Heart function is checked before and during treatment, and treatment is stopped or paused if it drops significantly.
  • Infusion reactions and lungs: Serious and fatal reactions can occur, usually during or within 24 hours of an infusion. Warning signs include trouble breathing, low blood pressure, and swelling of the face or throat. Treatment is stopped for anaphylaxis, angioedema, interstitial pneumonitis (lung inflammation), or acute respiratory distress syndrome.
  • Pregnancy: It can cause low amniotic fluid (oligohydramnios), which can lead to underdeveloped lungs, skeletal problems and newborn death. Effective birth control is needed.
Read the full warning on DailyMed →

Trastuzumab Injection by the Numbers

Strengths
3
in one form
Makers and packagers
5
Earliest FDA record
1998
Rank by Medicaid prescriptions
#659 of 1,682 drugs
More prescriptions than 60% of the 1,682 drugs we measure
46,422 prescriptions, Q1–Q4 2025

Patient Information Guide for Trastuzumab Injection

What It’s Used For

Trastuzumab Injection treats cancers that overexpress HER2, confirmed by an FDA-approved test.

  • Herzuma: adjuvant (early-stage) HER2-overexpressing breast cancer, node positive or node negative, as part of specific chemotherapy regimens or as a single agent after anthracycline-based therapy.
  • Herzuma: metastatic HER2-overexpressing breast cancer, with paclitaxel as first treatment or alone after prior chemotherapy for metastatic disease.
  • Herzuma: HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, with cisplatin and capecitabine or 5-fluorouracil, in people not previously treated for metastatic disease.

How It Works

HER2 is a receptor on the surface of cells that can drive tumor growth when there is too much of it. Trastuzumab products slow the growth of tumor cells that overexpress HER2.

They also trigger antibody-dependent cellular cytotoxicity (ADCC), in which immune cells attack the tumor cell. This effect is stronger against HER2-overexpressing cancer cells than against cells without extra HER2.

Drug Class

Drug Class

  • HER2/neu Receptor Antagonist
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.

Drug Class

Established Pharmacologic Class (EPC)
  • HER2/neu Receptor Antagonist

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • HER2/Neu/cerbB2 Antagonists

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Trastuzumab Injection in the FDA’s index.

From our Patient Information GuideHER2 is a receptor on the surface of cells that can drive tumor growth when there is too much of it. Trastuzumab products slow the growth of tumor cells that overexpress HER2. Read How Trastuzumab Injection Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)

None listed for Trastuzumab Injection in the FDA’s index.

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Herceptin and Its Biosimilars

The FDA has approved 6 biosimilars to Herceptin, the original trastuzumab, made by Genentech. It rates none of them interchangeable.

The original

Herceptin

trastuzumab

Made by Genentech · FDA‑approved 1998

Its 6 biosimilars

  • Ogivri trastuzumab-dkst Made by Biocon Biologics · FDA‑approved December 2017 Biosimilar, not rated interchangeable
  • Herzuma trastuzumab-pkrb Made by Celltrion · FDA‑approved December 2018 Biosimilar, not rated interchangeable
  • Ontruzant trastuzumab-dttb Made by Samsung Bioepis · FDA‑approved January 2019 Biosimilar, not rated interchangeable
  • Trazimera trastuzumab-qyyp Made by Pfizer Ireland Pharmaceuticals · FDA‑approved March 2019 Biosimilar, not rated interchangeable
  • Kanjinti trastuzumab-anns Made by Amgen · FDA‑approved June 2019 Biosimilar, not rated interchangeable
  • Hercessi trastuzumab-strf Made by Accord BioPharma · FDA‑approved April 2024 Biosimilar, not rated interchangeable

What Is a Biosimilar?

  • A biologic is made in living cells, not mixed from chemicals, so no copy of one is exactly identical. That is why a copy is called a biosimilar, not a generic.
  • The FDA approves a biosimilar only when it is highly similar to the original and has no clinically meaningful differences in safety or in how well it works.
  • It may be approved for fewer uses than the original, and may not come in every strength or device. Its own label lists what it is approved for.

What Does Interchangeable Mean?

  • An interchangeable biosimilar can be given in place of the original at the pharmacy without your prescriber writing a new prescription, where state law allows, the way a generic can.
  • A biosimilar without that rating works the same way, but needs a prescription written for it.

Why Four Letters After the Name?

  • The FDA gives each biologic it licenses now four letters of its own, such as the letters dkst in trastuzumab-dkst. They mean nothing on their own.
  • They tell one company’s product from another’s in your records and in safety reports.

Which one will I get? That depends on your prescription, your insurance plan and your pharmacy. Your pharmacist can tell you which one you have and whether a switch is possible.

From the FDA’s Purple Book, its list of licensed biologics, checked November 2026. The definitions follow the FDA’s biosimilar pages.

Dosage

Trastuzumab Injection is given as an IV infusion by a healthcare professional. Food does not apply.

  • Breast cancer: given weekly or every three weeks. Adjuvant treatment totals about one year, and extending beyond one year is not recommended.
  • Metastatic breast or gastric cancer: continues until the disease progresses.
  • The first infusion is longer than later ones. Infusions may be slowed or stopped if a reaction occurs.
  • Missed dose: if you are one week late or less, the usual dose is given as soon as possible. If more than a week late, a larger re-loading dose is given. Call your care team to reschedule.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Adjuvant breast cancer, during and following paclitaxel, docetaxel, or docetaxel and carboplatin: initial dose

Adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Initial dose Starting dose 4 mg/kg once
  • 4 mg/kg as an intravenous infusion over 90 minutes
Adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Every three weeks after the weekly doses Usual dose 6 mg/kg every three weeks
  • 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks, starting one week following the last weekly dose, for a total of 52 weeks of therapy

Good to know

Extending adjuvant treatment beyond one year is not recommended

Early-stage HER2-positive breast cancer (after surgery)

For adults given with paclitaxel, docetaxel, or docetaxel and carboplatin · Weekly doses during chemotherapy
Usual dose 2 mg/kg once a week
  • 2 mg/kg as an intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel and carboplatin)

Adjuvant breast cancer, as a single agent within three weeks following multi-modality, anthracycline-based chemotherapy: initial dose

Adults given alone after anthracycline-based chemotherapy · Initial dose Starting dose 8 mg/kg once
  • 8 mg/kg as an intravenous infusion over 90 minutes
Adults given alone after anthracycline-based chemotherapy · Subsequent doses Usual dose 6 mg/kg every three weeks
  • 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks

Good to know

Total of 52 weeks of therapy; extending beyond one year is not recommended

Metastatic breast cancer, alone or in combination with paclitaxel: initial dose

For adults · Initial dose
Starting dose 4 mg/kg once
  • 4 mg/kg as a 90-minute intravenous infusion

HER2-positive breast cancer that has spread

For adults · Subsequent weekly doses
Usual dose 2 mg/kg once a week
  • 2 mg/kg as 30-minute intravenous infusions once weekly until disease progression

Metastatic gastric cancer: initial dose

For adults · Initial dose
Starting dose 8 mg/kg once
  • 8 mg/kg as a 90-minute intravenous infusion

Metastatic gastric cancer: subsequent doses

For adults · Subsequent doses
Usual dose 6 mg/kg every three weeks
  • 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease progression

See the Full Dosing Instructions on DailyMed →

Side Effects

Common side effects vary by cancer type and by the chemotherapy given with it.

Common side effects

  • Fever and chills
  • Nausea and vomiting
  • Diarrhea
  • Headache
  • Fatigue or weakness
  • Cough and shortness of breath
  • Rash
  • Infections and low white blood cell counts (neutropenia)
  • Muscle pain (myalgia)

When to get medical help

  • Call your doctor right away for new shortness of breath, swelling in the legs or ankles, rapid heartbeat or palpitations, or sudden weight gain, which can be signs of heart problems.
  • Tell your care team immediately during or after an infusion if you have trouble breathing, dizziness, lightheadedness, facial or throat swelling, or severe rash. Serious and fatal infusion reactions can occur, usually within 24 hours.
  • Report new or worsening cough, trouble breathing, or breathing problems, which may signal lung toxicity.
  • Call right away if you have fever or signs of infection, since trastuzumab can worsen chemotherapy-related low white blood cell counts.
  • Tell your doctor right away if you are or may be pregnant.

Warnings and Precautions

  • Heart problems: trastuzumab can cause cardiomyopathy, heart failure, arrhythmias and a drop in LVEF, especially with anthracyclines. Heart function is tested before and during treatment.
  • Infusion reactions: can be serious or fatal, usually during or within 24 hours of an infusion.
  • Lung toxicity: includes pneumonitis, fluid around the lungs and ARDS. People with lung disease or extensive lung tumors may have more severe reactions.
  • Pregnancy harm: can cause oligohydramnios and fetal harm.
  • Neutropenia: low white blood cell counts may be worse when it is combined with chemotherapy.

Interactions

No formal drug interaction studies were done in humans, but anthracyclines are an important concern.

  • Anthracyclines (such as doxorubicin): raise the risk of heart problems, including after trastuzumab is stopped because it clears slowly.
  • Ado-trastuzumab emtansine and fam-trastuzumab deruxtecan: different drugs, never interchangeable with trastuzumab products.
  • Paclitaxel, docetaxel, carboplatin, cisplatin, capecitabine: levels were not changed by trastuzumab in studies.

Interactions Listed in the FDA-Approved Label

From the Trastuzumab Injection prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Anthracyclines
    What happensPatients who receive an anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab's long washout period.
    What to doIf possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products; if anthracyclines are used, monitor cardiac function carefully.
Read the label’s full interactions text

7 DRUG INTERACTIONS Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab’s long washout period based on population PK analysis. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, the patient’s cardiac function should be monitored carefully.

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Tell your doctor about heart or lung disease.
  • Pregnancy status is checked before starting. Use effective birth control during treatment and for 7 months after the last dose.
  • If breastfeeding, discuss benefits and risks with your doctor.
  • Adults 65 and over had a higher risk of heart dysfunction.
  • Safety and effectiveness in children have not been established.
  • No contraindications are listed.

Overdose

There is no experience with overdose in human clinical trials. Single doses higher than 8 mg/kg have not been tested.

How Your Body Processes It

Trastuzumab is cleared by two pathways, and clearance increases as drug levels fall. Steady-state levels were reached in about 9 to 12 weeks in the studies. After stopping, levels fall to about 3% of steady-state levels by 7 months in most patients, which is why precautions last that long.

Age, race and mild to moderate kidney impairment did not cause meaningful differences. Effects of severe kidney impairment or liver impairment are unknown.

Storage

Store Herceptin vials in the refrigerator at 2°C to 8°C (36°F to 46°F) until time of reconstitution.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Trastuzumab Injection: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Trastuzumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.

What is trastuzumab injection used for?

It treats breast cancer and stomach (gastric or gastroesophageal junction) cancer when the tumor has too much of a protein called HER2. Your tumor is tested first to confirm this. It is often given along with chemotherapy.

How is trastuzumab injection given?

It is given as a slow IV infusion by your care team, never as a quick push. Depending on your cancer, you get it weekly or every three weeks. The first infusion takes longer, and they watch you for reactions.

What happens if I miss a dose of trastuzumab injection?

Call your care team as soon as you can. If you are one week late or less, you usually get your regular dose right away. If it has been more than a week, you may need a larger re-loading dose over about 90 minutes.

What side effects should I expect, and which should I call about?

Fever, chills, nausea, diarrhea, headache, tiredness and rash are common. Call right away for shortness of breath, leg swelling, a racing heartbeat, facial or throat swelling, or signs of infection. These can signal heart, lung or infusion problems.

Is it safe during pregnancy?

No. It can cause low amniotic fluid and serious harm to a baby, including lung and skeletal problems. Use effective birth control during treatment and for 7 months after your last dose. Tell your doctor right away if you could be pregnant.

How long does Trastuzumab stay in my body?

A long time. Levels drop to about 3% of steady-state by roughly 7 months after your last dose. That is why birth control continues for 7 months, and why doctors avoid anthracycline chemotherapy for up to 7 months afterward if possible.

Is trastuzumab injection available over the counter?

No. Trastuzumab injection is a prescription medicine: every trastuzumab injection product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was trastuzumab injection first available?

The earliest FDA record we hold for trastuzumab injection is from 1998: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when trastuzumab injection was first used.

Who makes trastuzumab injection?

5 companies currently list trastuzumab injection products in the FDA's NDC Directory, including Biocon Biologics Inc., Cephalon, Inc., Genentech, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of trastuzumab injection?

Trastuzumab injection is the generic name. Its brand names are Herceptin, Herzuma, Kanjinti, Ogivri, Trazimera and 2 more. Of these, Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti and Hercessi are biosimilars to Herceptin, not brand names of Herceptin itself.

What is the generic name of Herceptin?

The generic name of Herceptin is trastuzumab injection. A generic name is the name of the active ingredient, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is trastuzumab injection?

Trastuzumab injection belongs to the drug class HER2/neu Receptor Antagonist, its established pharmacologic class on the FDA label. The FDA also groups it by how it works: HER2/Neu/cerbB2 Antagonist.

What strengths does trastuzumab injection come in?

Trastuzumab injection is listed in the FDA's National Drug Code Directory in these forms and strengths. Injection (into a vein): 150 mg, 150 mg/7.4 mL and 150 mg/7.15 mL. A listing does not mean every pharmacy stocks every strength.

Where can I read the trastuzumab injection prescribing information (package insert)?

The full FDA-approved prescribing information for trastuzumab injection, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Genentech, Inc.'s, revised May 29, 2026, and links to it on DailyMed.

Is there a biosimilar for Herceptin?

Yes. The FDA has approved 6 biosimilars to Herceptin: Ogivri (trastuzumab-dkst), Herzuma (trastuzumab-pkrb), Ontruzant (trastuzumab-dttb), Trazimera (trastuzumab-qyyp), Kanjinti (trastuzumab-anns) and Hercessi (trastuzumab-strf). Which one you get depends on your prescription, your insurance plan and your pharmacy.

Is trastuzumab injection gluten free?

No trastuzumab injection label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 5 trastuzumab injection products from 5 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's trastuzumab injection by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See trastuzumab injection inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Trastuzumab Injection

Skip the scrolling. Ask in your own words and get an answer from Trastuzumab Injection’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Trastuzumab Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Trastuzumab Injection on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Trastuzumab Injection Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Trastuzumab Injection Forms and Strengths (How It Comes)

Trastuzumab Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Trastuzumab Injection inactive ingredients by manufacturer.

Injection

Into a vein
Brands Herceptin Herzuma Ogivri Ontruzant
How this form is used
What it may be used for
  • Herzuma is used in adults for HER2-overexpressing breast cancer, including adjuvant and metastatic settings.
  • Herzuma is also used with cisplatin and capecitabine or 5-fluorouracil for HER2-overexpressing metastatic gastric or gastroesophageal junction cancer in people not previously treated for metastatic disease.
Important instructions
  • Herzuma is for IV infusion only and must not be given as an IV push or bolus.
  • Herzuma has different dosing and administration instructions than subcutaneous trastuzumab products.
  • Herzuma must not be substituted for or with ado-trastuzumab emtansine or fam-trastuzumab deruxtecan.
  • Herzuma is not mixed with other drugs and is diluted in 0.9% sodium chloride, not dextrose.
Available strengths 3 strengths
4 FDA-listed product records ⓘ

Trastuzumab Injection on the U.S. Market: Products, Makers and Brands

How Trastuzumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

5 companies list 5 Trastuzumab Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1998. Brand names in the directory today include Herceptin, Herzuma, Ogivri and 1 more; the rest are generics.

1
Dose forms ⓘ
5
Labelers (makers, repackagers, distributors)
7
Brand names ⓘ
5
FDA-listed product records ⓘ
1998
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished injection (2) · Unfinished injection, powder, lyophilized, for solution (1) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Biocon Biologics Inc.20%
Cephalon, Inc.20%
Genentech, Inc.20%
Mylan Institutional LLC20%
Organon LLC20%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Trastuzumab Injection Is Used (Medicaid Data)

How many Trastuzumab Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

46,422
Medicaid prescriptions filled (Q1–Q4 2025)
$229M paid by Medicaid, before rebates

How commonly is Trastuzumab Injection prescribed? Of the 1,682 medications we measure, Trastuzumab Injection ranks #659 by Medicaid prescriptions — more than 61% of them.

Where Trastuzumab Injection ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Trastuzumab Injection product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 100 mg injection is the most-dispensed Trastuzumab Injection product — about 38% of these Medicaid prescriptions.

fam-trastuzumab deruxtecan-nxki 100 MG Injection Most dispensed

17,489 Medicaid prescriptions (Q1–Q4 2025) 38% of Trastuzumab Injection prescriptions shown $129.1M paid by Medicaid, before rebates ≈ $7,383 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2267576

trastuzumab-dkst 21 MG/ML Injectable Solution

5,479 Medicaid prescriptions (Q1–Q4 2025) 12% of Trastuzumab Injection prescriptions shown $14.3M paid by Medicaid, before rebates ≈ $2,605 per prescription, before rebates

2 of 5 listed NDCs had Medicaid claims. RxNorm 2179760

trastuzumab 150 MG Injection

4,780 Medicaid prescriptions (Q1–Q4 2025) 10% of Trastuzumab Injection prescriptions shown $17M paid by Medicaid, before rebates ≈ $3,560 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 1922509

ado-trastuzumab emtansine 100 MG Injection

4,616 Medicaid prescriptions (Q1–Q4 2025) 10% of Trastuzumab Injection prescriptions shown $32M paid by Medicaid, before rebates ≈ $6,929 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1658084

trastuzumab-qyyp 21 MG/ML Injectable Solution

4,171 Medicaid prescriptions (Q1–Q4 2025) 9% of Trastuzumab Injection prescriptions shown $5.7M paid by Medicaid, before rebates ≈ $1,359 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2280732

trastuzumab-anns 21 MG/ML Injectable Solution

3,858 Medicaid prescriptions (Q1–Q4 2025) 8% of Trastuzumab Injection prescriptions shown $9.4M paid by Medicaid, before rebates ≈ $2,429 per prescription, before rebates

2 of 3 listed NDCs had Medicaid claims. RxNorm 2174804

ado-trastuzumab emtansine 160 MG Injection

1,879 Medicaid prescriptions (Q1–Q4 2025) 4% of Trastuzumab Injection prescriptions shown $13.2M paid by Medicaid, before rebates ≈ $7,006 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 1658089

trastuzumab-anns 150 MG Injection

1,355 Medicaid prescriptions (Q1–Q4 2025) 3% of Trastuzumab Injection prescriptions shown $3.3M paid by Medicaid, before rebates ≈ $2,419 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2257297

trastuzumab-dkst 150 MG Injection

1,046 Medicaid prescriptions (Q1–Q4 2025) 2% of Trastuzumab Injection prescriptions shown $1.9M paid by Medicaid, before rebates ≈ $1,834 per prescription, before rebates

2 of 2 listed NDCs had Medicaid claims. RxNorm 2179753

trastuzumab-qyyp 150 MG Injection

893 Medicaid prescriptions (Q1–Q4 2025) 2% of Trastuzumab Injection prescriptions shown $1.2M paid by Medicaid, before rebates ≈ $1,369 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2472791

trastuzumab-dttb 21 MG/ML Injectable Solution

276 Medicaid prescriptions (Q1–Q4 2025) <1% of Trastuzumab Injection prescriptions shown $577,351 paid by Medicaid, before rebates ≈ $2,092 per prescription, before rebates

1 of 3 listed NDCs had Medicaid claims. RxNorm 2289234

trastuzumab-dttb 150 MG Injection

118 Medicaid prescriptions (Q1–Q4 2025) <1% of Trastuzumab Injection prescriptions shown $484,391 paid by Medicaid, before rebates ≈ $4,105 per prescription, before rebates

1 of 4 listed NDCs had Medicaid claims. RxNorm 2289227

trastuzumab-pkrb 21 MG/ML Injectable Solution

88 Medicaid prescriptions (Q1–Q4 2025) <1% of Trastuzumab Injection prescriptions shown $258,277 paid by Medicaid, before rebates ≈ $2,935 per prescription, before rebates

1 of 2 listed NDCs had Medicaid claims. RxNorm 2107053

trastuzumab-pkrb 150 MG Injection

31 Medicaid prescriptions (Q1–Q4 2025) <1% of Trastuzumab Injection prescriptions shown $64,203 paid by Medicaid, before rebates ≈ $2,071 per prescription, before rebates

1 of 1 listed NDCs had Medicaid claims. RxNorm 2169359

Other Trastuzumab Injection products: packs and listings not matched to one strength and form

343 Medicaid prescriptions (Q1–Q4 2025) <1% of Trastuzumab Injection prescriptions shown $614,576 paid by Medicaid, before rebates ≈ $1,792 per prescription, before rebates

2 of 17 listed NDCs had Medicaid claims.

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 19 of the 47 listed Trastuzumab Injection NDCs had Medicaid claims.

Compare Trastuzumab Injection Products

A representative set of FDA-listed product records for Trastuzumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Injection
150 mg/7.4 mL Intravenous Biocon Biologics Inc. BLA View NDC →
150 mg/7.15 mL Intravenous Cephalon, Inc. BLA View NDC →
150 mg/7.4 mL Intravenous Genentech, Inc. BLA View NDC →
150 mg/7.4 mL Intravenous Mylan Institutional LLC BLA View NDC →
150 mg Intravenous Organon LLC BLA View NDC →

Showing 5 of 5 products — FDA National Drug Code Directory. See every product, package size and price: browse all 5 Trastuzumab Injection NDCs →

Trastuzumab Injection Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Trastuzumab recalls since July 2021.

✅No Trastuzumab recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Trastuzumab Injection in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.

Dose forms
2
Strengths
17
Forms in current FDA listings
2 of 2
In current FDA listings No current FDA listing
Ingredient (IN) Trastuzumab Injection RxCUI 224905
  1. Dose form (SCDF) Injectable Solution RxCUI 377216
    In current FDA listings
    Its 7 strengths (SCD)
  2. Dose form (SCDF) Injection RxCUI 1922508
    In current FDA listings
    Its 10 strengths (SCD)
    • 150 mg RxCUI 1922509
    • 100 mg ado-trastuzumab emtansine RxCUI 1658084
    • 160 mg ado-trastuzumab emtansine RxCUI 1658089
    • 150 mg anns RxCUI 2257297
    • 150 mg dkst RxCUI 2179753
    • 150 mg dttb RxCUI 2289227
    • 100 mg fam-trastuzumab deruxtecan-nxki RxCUI 2267576
    • 150 mg pkrb RxCUI 2169359
    • 150 mg qyyp RxCUI 2472791
    • 150 mg strf RxCUI 2700718

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Trastuzumab Injection Brand Names

Trastuzumab Injection has 7 brand names on record: Herceptin, Herzuma, Kanjinti, Ogivri and others. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Herceptin Herzuma Kanjinti Ogivri Trazimera Ontruzant Hercessi

Who Makes Trastuzumab Injection: Manufacturers and Labelers

5 companies list Trastuzumab Injection products with the FDA. By number of product records, the largest are Biocon Biologics Inc., Cephalon, Inc., Genentech, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Biocon Biologics Inc. 1 Cephalon, Inc. 1 Genentech, Inc. 1 Mylan Institutional LLC 1 Organon LLC 1

Sources for This Trastuzumab Injection Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated May 29, 2026, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Trastuzumab Injection.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 4 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
4
Finished products in the current FDA directory
5
Companies listing them (makers, repackagers, distributors)
5
FDA labeler codes behind them ⓘ
5
Linked representative label ⓘ
Genentech, Inc.
Linked label effective
May 29, 2026
Composite sections available
23
Linked SPL Set ID
492dbdb2-077e-4064-bff3-372d6af0a7a2
Linked SPL Document ID
7517f775-6a10-4ddd-8dfb-6704ece413d0
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Genentech, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →